• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JULY 18, 2000

Sun Pharma: Continues to outpace industry

Sun Pharma continued its good run, outpacing the overall pharmaceutical industry. While the topline shot up by over 28%, the bottomline grew by a mind boggling 55%.

During the quarter the amalgamated the operations of Gujarat Lyka by allotting 0.47 m shares in the ratio of 1 share for every 21.33 shares of Gujarat Lyka. If one were to account for the fact that the sales figures for corresponding quarter in the previous year, did not include domestic bulk drug sales of Rs. 61.3 m of Gujarat Lyka, the topline growth comes to around 21.6%, which is still very creditable. The earnings also include the profit of Sun Pharmaceutical Exports, a 99.28% subsidiary of the company which is proposed to be merged with the company with effect from April 2000.

(Rs m) 1QFY00 1QFY01 Change
Sales 1,029 1,327 28.9%
Other Income 4 5 32.4%
Expenditure 782 967 23.6%
Operating Profit (EBDIT) 247 360 45.5%
Operating Profit Margin (%) 24.0% 27.1%  
Interest (net) 7 (3)  
Depreciation 27 38 38.9%
Profit before Tax 217 330 52.0%
Other Adjustments      
Tax 17 20 16.0%
Profit after Tax/(Loss) 200 311 55.1%
Net profit margin (%) 19.5% 23.4%  
No. of Shares (m) (eoy) 15.4 46.7  
Diluted no. of shares (m) 46.7 46.7  
Diluted Earnings per share* 17.1 26.6  
*(annualised)      

Coming to the operations themselves the company is currently ranked 5th by retail prescription sales, up from 10th position last year (ORG Retail Chemist Audit, May 2000 & 1999) . Six of the company's speciality brands feature in the top-selling list of 300 pharma brands in the domestic market.

During the quarter the company launched seven new products key among these were the Cox 2 inhibitor for the treatment of arthritis, Rofact (rofecoxib), the type 2 oral antidiabetic Glypride (glimiperide), Nodict (naltrexone) for use in drug abuse treatments, the allergy treatment Fexotrol (fexofenadine). Milmet's range was enhanced with the addition of Azelast eyedrops (azelastine), and Ketorid eye drops (ketotifen).

The management has made a statement that their strategy of focus on niche specialty areas would continue in the near future too and they are confident of maintaining double the industry growth rate for the year.

The stock quotes at Rs 595, which discounts the annualised earnings by 21.4 times.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407